Analyst consensus rating

Akari Therapeutics Analyst Rating: Strong Buy

Direct answer

Akari Therapeutics's consensus rating is Strong Buy.

3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $25.50.
Forecast evidence checked November 17, 2026.

Get free Akari Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$6.51
Average price target
$25.50
High price target
$30.00
Low price target
$19.50
Low target gap
+199.5%
Target upside
+291.7%
High target gap
+360.8%
Target range width
161.3%
Consensus rating
Strong Buy
Analysts
3
Evidence date
November 17, 2026
Valid through
November 24, 2026

Read the frequently asked questions.

What is the analyst consensus rating for Akari Therapeutics?

Akari Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $25.50.

How far are Akari Therapeutics's low and high targets from the recorded price?

The low target implies +199.5%, while the high target implies +360.8%.

How many analysts are included in Akari Therapeutics's consensus?

The verified consensus includes 3 analysts.

How is Akari Therapeutics's target upside or downside calculated?

The average target of $25.50 is divided by the recorded price of $6.51, then one is subtracted to produce +291.7%. This does not guarantee a future return.

When was Akari Therapeutics's analyst forecast verified?

The data was verified on 2026-11-17. The dataset is valid through 2026-11-24.